(Photo credits: Pixabay – fernando zhiminaicela)
(AOF) – AB Science (-11.95% to 3.39 euros) posts one of the biggest drops in the SRD market after announcing that the Committee for Medicinal Products for Human Use (CHMP) of Ema (European Medicines Agency ) asked it to respond in writing to questions remaining unanswered about its masitinib product instead of addressing these questions during the oral explanation scheduled for January 24, 2024. The biotech is requesting the marketing of masitinib against lateral sclerosis amyotrophic.